Functional Analysis of a Chromosomal Deletion Associated with Myelodysplastic Syndromes Using Isogenic Human Induced Pluripotent Stem Cells

Total Page:16

File Type:pdf, Size:1020Kb

Functional Analysis of a Chromosomal Deletion Associated with Myelodysplastic Syndromes Using Isogenic Human Induced Pluripotent Stem Cells ARTICLES Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells Andriana G Kotini1–3, Chan-Jung Chang1–3,19, Ibrahim Boussaad4,5,19, Jeffrey J Delrow6, Emily K Dolezal7, Abhinav B Nagulapally5,8, Fabiana Perna9, Gregory A Fishbein5,10, Virginia M Klimek11, R David Hawkins5,8, Danwei Huangfu12, Charles E Murry5,13–16, Timothy Graubert17, Stephen D Nimer7 & Eirini P Papapetrou1–5,13,18 Chromosomal deletions associated with human diseases, such as cancer, are common, but synteny issues complicate modeling of these deletions in mice. We use cellular reprogramming and genome engineering to functionally dissect the loss of chromosome 7q (del(7q)), a somatic cytogenetic abnormality present in myelodysplastic syndromes (MDS). We derive del(7q)- and isogenic karyotypically normal induced pluripotent stem cells (iPSCs) from hematopoietic cells of MDS patients and show that the del(7q) iPSCs recapitulate disease-associated phenotypes, including impaired hematopoietic differentiation. These disease phenotypes are rescued by spontaneous dosage correction and can be reproduced in karyotypically normal cells by engineering hemizygosity of defined chr7q segments in a 20-Mb region. We use a phenotype-rescue screen to identify candidate haploinsufficient genes that might mediate the del(7q)- hematopoietic defect. Our approach highlights the utility of human iPSCs both for functional mapping of disease-associated large-scale chromosomal deletions and for discovery of haploinsufficient genes. Large hemizygous deletions are found in most tumors and might if the mechanism fits a “classic” recessive (satisfying Knudson’s “two- be both hallmarks and drivers of cancer1. Hemizygous segmental hit” hypothesis) or a haploinsufficiency model and, finally, identifying chromosomal deletions are also frequent in normal genomes2. Apart the specific genetic elements that are lost. Classic tumor suppressor Nature America, Inc. All rights reserved. America, Inc. Nature from rare prototypic deletion syndromes (e.g., Smith-Magenis, genes were discovered through physical mapping of homozygous 5 Williams-Beuren, 22q11 deletion syndromes), genome-wide asso- deletions5. More recent data suggest that sporadic tumor suppressor ciation studies (GWAS) have implicated genomic deletions in neuro- genes are more likely to be mono-allelically lost and to function © 201 developmental diseases like schizophrenia and autism3, prompting through haploinsufficiency (wherein a single functional copy of a the hypothesis that deletions might account for an important source gene is insufficient to maintain normal function)6,7. of the ‘missing heritability’ of complex diseases3,4. MDS are clonal hematologic disorders characterized by ineffec- npg Unlike translocations or point mutations, chromosomal deletions are tive hematopoiesis and a propensity for progression to acute myeloid difficult to study with existing tools because primary patient material leukemia (AML)8. Somatic loss of one copy of the long arm of chro- is often scarce, and incomplete conservation of synteny (homologous mosome 7 (del(7q)) is a characteristic cytogenetic abnormality in genetic loci can be present on different chromosomes or in different MDS, well-recognized for decades as a marker of unfavorable progno- physical locations relative to each other within a chromosome across sis. However, the role of del(7q) in the pathogenesis of MDS remains species) complicate modeling in mice. Dissecting the role of specific elusive. The deletions are typically large and dispersed along the entire chromosomal deletions in specific cancers entails, first, determin- long arm of chr7 (ref. 9). Homology for human chr7q maps to four ing if a deletion has phenotypic consequences; second, determining different mouse chromosomes. 1Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 2The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 3The Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 4Division of Hematology, Department of Medicine, University of Washington, Seattle, Washington, USA. 5Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, Washington, USA. 6Genomics Resource, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 7Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida, USA. 8Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington, USA. 9Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. 10Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. 11Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. 12Developmental Biology Program, Sloan-Kettering Institute, New York, New York, USA. 13Department of Pathology, University of Washington, Seattle, Washington, USA. 14Center for Cardiovascular Biology, University of Washington, Seattle, Washington, USA. 15Department of Bioengineering University of Washington, Seattle, Washington, USA. 16Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA. 17MGH Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA. 18Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 19These authors contributed equally to this work. Correspondence should be addressed to E.P.P. ([email protected]). Received 6 November 2014; accepted 13 February 2015; published online 23 March 2015; doi:10.1038/nbt.3178 646 VOLUME 33 NUMBER 6 JUNE 2015 NATURE BIOTECHNOLOGY ARTICLES Genetic engineering of human pluripotent stem cells (hPSCs) has in BMMCs and fibroblasts, and variants with variant allele frequency been used to model point mutations causing monogenic diseases in >1% in fibroblasts or <10% in BMMCs (Fig. 1e and Supplementary an isogenic setting10,11, but not disease-associated genomic deletions. Table 4). Similarly, 73 and 48 somatic SNVs were identified in the We used reprogramming and chromosome engineering to model del(7q)- and isogenic normal iPSC line, respectively. The del(7q)- del(7q) in an isogenic setting in hPSCs. Using different isogenic pairs iPSC line contained all 34 variants of the MDS clone, whereas the iso- of hPSCs harboring one or two copies of chr7q, we characterized genic normal line harbored none. These variants included two genes hematopoietic defects mediated by del(7q). We used spontaneous found recurrently mutated in MDS, SRSF2 and PHF6. Resequencing rescue and genome editing experiments to show that these pheno- of the rest of the iPSC lines derived from this patient (Supplementary types are mediated by a haploid dose of chr7q material, consistent Table 2) showed that all of the del(7q)- (6 out of 6) and none of with haploinsufficiency of one or more genes. We functionally map a the karyotypically normal iPSC lines (0 out of 15) harbored these 20-Mb fragment spanning cytobands 7q32.3–7q36.1 as the crucial mutations. These results unequivocally demonstrate that the isogenic region and identify candidate disease-specific haploinsufficient genes iPSCs represent normal cells that contain no premalignant lesions and using a phenotype-rescue screen. Finally, we show that the hemato- that the del(7q)- iPSCs accurately capture the genetic composition of poietic defect is mediated by the combined haploinsufficiency of the MDS clone. EZH2, in cooperation with one or more out of three additional candi- date genes residing in this region. The strategy reported here could be Decreased hematopoietic differentiation of del(7q)- MDS iPSCs applied to study the phenotypic consequences of segmental chromo- To assess the hematopoietic differentiation potential of the MDS somal deletions and for haploinsufficient gene discovery in a variety iPSCs we optimized an embryoid body–based differentiation pro- of human cancers, and neurological and developmental diseases. tocol and monitored the course of differentiation using CD34, a hemato-endothelial marker, and CD45, the key marker of definitive RESULTS hematopoietic cells15. In this differentiation protocol, normal human Generation of del(7q)- and normal isogenic iPSCs embryonic stem cell (hESC) and iPSC lines typically express CD34 We derived iPSC lines from hematopoietic cells of two patients (patients by day 6. Co-expression of CD45 appears by day 10, peaks at no. 2 and no. 3) with del(7q)- MDS (Fig. 1 and Supplementary Tables 1 day 14, and is followed by loss of CD34, as the cells become more and 2). We reasoned that residual normal hematopoietic cells are differentiated along hematopoietic lineages. By day 18, typically likely to co-exist with the MDS clone in the bone marrow of MDS more than 90% of cells are CD45+ (Supplementary Fig. 2a). We patients and that we could exploit this to reprogram both del(7q)- assessed the intra- (Supplementary Fig. 2a,b, panels I, II and c) and and isogenic karyotypically normal cells in parallel. We were able to inter- (Supplementary Fig. 2a,b, panels III, IV) line variation in this derive del(7q)- and karyotypically normal (N-) iPSC lines at the same differentiation process using normal iPSC lines derived from bone reprogramming round from both
Recommended publications
  • CREB-Binding Protein Regulates Lung Cancer Growth by Targeting MAPK and CPSF4 Signaling Pathway
    MOLECULAR ONCOLOGY 10 (2016) 317e329 available at www.sciencedirect.com ScienceDirect www.elsevier.com/locate/molonc CREB-binding protein regulates lung cancer growth by targeting MAPK and CPSF4 signaling pathway Zhipeng Tanga,1, Wendan Yua,1, Changlin Zhangb,1, Shilei Zhaoa, Zhenlong Yua, Xiangsheng Xiaob, Ranran Tanga, Yang Xuana, Wenjing Yanga, Jiaojiao Haoa, Tingting Xua, Qianyi Zhanga, Wenlin Huangb,c, Wuguo Dengb,c,*, Wei Guoa,* aInstitute of Cancer Stem Cell, Dalian Medical University, Dalian, China bSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China cState Key Laboratory of Targeted Drug for Tumors of Guangdong Province, Guangzhou Double Bioproduct Inc., Guangzhou, China ARTICLE INFO ABSTRACT Article history: CBP (CREB-binding protein) is a transcriptional co-activator which possesses HAT (histone Received 15 September 2015 acetyltransferases) activity and participates in many biological processes, including embry- Accepted 19 October 2015 onic development, growth control and homeostasis. However, its roles and the underlying Available online 5 November 2015 mechanisms in the regulation of carcinogenesis and tumor development remain largely unknown. Here we investigated the molecular mechanisms and potential targets of CBP Keywords: involved in tumor growth and survival in lung cancer cells. Elevated expression of CBP CBP was detected in lung cancer cells and tumor tissues compared to the normal lung cells CPSF4 and tissues. Knockdown of CBP by siRNA or inhibition of its HAT activity using specific hTERT chemical inhibitor effectively suppressed cell proliferation, migration and colony forma- Lung cancer tion and induced apoptosis in lung cancer cells by inhibiting MAPK and activating cyto- chrome C/caspase-dependent signaling pathways.
    [Show full text]
  • Analysis of Trans Esnps Infers Regulatory Network Architecture
    Analysis of trans eSNPs infers regulatory network architecture Anat Kreimer Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2014 © 2014 Anat Kreimer All rights reserved ABSTRACT Analysis of trans eSNPs infers regulatory network architecture Anat Kreimer eSNPs are genetic variants associated with transcript expression levels. The characteristics of such variants highlight their importance and present a unique opportunity for studying gene regulation. eSNPs affect most genes and their cell type specificity can shed light on different processes that are activated in each cell. They can identify functional variants by connecting SNPs that are implicated in disease to a molecular mechanism. Examining eSNPs that are associated with distal genes can provide insights regarding the inference of regulatory networks but also presents challenges due to the high statistical burden of multiple testing. Such association studies allow: simultaneous investigation of many gene expression phenotypes without assuming any prior knowledge and identification of unknown regulators of gene expression while uncovering directionality. This thesis will focus on such distal eSNPs to map regulatory interactions between different loci and expose the architecture of the regulatory network defined by such interactions. We develop novel computational approaches and apply them to genetics-genomics data in human. We go beyond pairwise interactions to define network motifs, including regulatory modules and bi-fan structures, showing them to be prevalent in real data and exposing distinct attributes of such arrangements. We project eSNP associations onto a protein-protein interaction network to expose topological properties of eSNPs and their targets and highlight different modes of distal regulation.
    [Show full text]
  • Novel Gene Fusions in Glioblastoma Tumor Tissue and Matched Patient Plasma
    cancers Article Novel Gene Fusions in Glioblastoma Tumor Tissue and Matched Patient Plasma 1, 1, 1 1 1 Lan Wang y, Anudeep Yekula y, Koushik Muralidharan , Julia L. Small , Zachary S. Rosh , Keiko M. Kang 1,2, Bob S. Carter 1,* and Leonora Balaj 1,* 1 Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, USA; [email protected] (L.W.); [email protected] (A.Y.); [email protected] (K.M.); [email protected] (J.L.S.); [email protected] (Z.S.R.); [email protected] (K.M.K.) 2 School of Medicine, University of California San Diego, San Diego, CA 92092, USA * Correspondence: [email protected] (B.S.C.); [email protected] (L.B.) These authors contributed equally. y Received: 11 March 2020; Accepted: 7 May 2020; Published: 13 May 2020 Abstract: Sequencing studies have provided novel insights into the heterogeneous molecular landscape of glioblastoma (GBM), unveiling a subset of patients with gene fusions. Tissue biopsy is highly invasive, limited by sampling frequency and incompletely representative of intra-tumor heterogeneity. Extracellular vesicle-based liquid biopsy provides a minimally invasive alternative to diagnose and monitor tumor-specific molecular aberrations in patient biofluids. Here, we used targeted RNA sequencing to screen GBM tissue and the matched plasma of patients (n = 9) for RNA fusion transcripts. We identified two novel fusion transcripts in GBM tissue and five novel fusions in the matched plasma of GBM patients. The fusion transcripts FGFR3-TACC3 and VTI1A-TCF7L2 were detected in both tissue and matched plasma.
    [Show full text]
  • Stelios Pavlidis3, Matthew Loza3, Fred Baribaud3, Anthony
    Supplementary Data Th2 and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in UBIOPRED Chih-Hsi Scott Kuo1.2, Stelios Pavlidis3, Matthew Loza3, Fred Baribaud3, Anthony Rowe3, Iaonnis Pandis2, Ana Sousa4, Julie Corfield5, Ratko Djukanovic6, Rene 7 7 8 2 1† Lutter , Peter J. Sterk , Charles Auffray , Yike Guo , Ian M. Adcock & Kian Fan 1†* # Chung on behalf of the U-BIOPRED consortium project team 1Airways Disease, National Heart & Lung Institute, Imperial College London, & Biomedical Research Unit, Biomedical Research Unit, Royal Brompton & Harefield NHS Trust, London, United Kingdom; 2Department of Computing & Data Science Institute, Imperial College London, United Kingdom; 3Janssen Research and Development, High Wycombe, Buckinghamshire, United Kingdom; 4Respiratory Therapeutic Unit, GSK, Stockley Park, United Kingdom; 5AstraZeneca R&D Molndal, Sweden and Areteva R&D, Nottingham, United Kingdom; 6Faculty of Medicine, Southampton University, Southampton, United Kingdom; 7Faculty of Medicine, University of Amsterdam, Amsterdam, Netherlands; 8European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL, Université de Lyon, France. †Contributed equally #Consortium project team members are listed under Supplementary 1 Materials *To whom correspondence should be addressed: [email protected] 2 List of the U-BIOPRED Consortium project team members Uruj Hoda & Christos Rossios, Airways Disease, National Heart & Lung Institute, Imperial College London, UK & Biomedical Research Unit, Biomedical Research Unit, Royal
    [Show full text]
  • Dual Proteome-Scale Networks Reveal Cell-Specific Remodeling of the Human Interactome
    bioRxiv preprint doi: https://doi.org/10.1101/2020.01.19.905109; this version posted January 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Dual Proteome-scale Networks Reveal Cell-specific Remodeling of the Human Interactome Edward L. Huttlin1*, Raphael J. Bruckner1,3, Jose Navarrete-Perea1, Joe R. Cannon1,4, Kurt Baltier1,5, Fana Gebreab1, Melanie P. Gygi1, Alexandra Thornock1, Gabriela Zarraga1,6, Stanley Tam1,7, John Szpyt1, Alexandra Panov1, Hannah Parzen1,8, Sipei Fu1, Arvene Golbazi1, Eila Maenpaa1, Keegan Stricker1, Sanjukta Guha Thakurta1, Ramin Rad1, Joshua Pan2, David P. Nusinow1, Joao A. Paulo1, Devin K. Schweppe1, Laura Pontano Vaites1, J. Wade Harper1*, Steven P. Gygi1*# 1Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA. 2Broad Institute, Cambridge, MA, 02142, USA. 3Present address: ICCB-Longwood Screening Facility, Harvard Medical School, Boston, MA, 02115, USA. 4Present address: Merck, West Point, PA, 19486, USA. 5Present address: IQ Proteomics, Cambridge, MA, 02139, USA. 6Present address: Vor Biopharma, Cambridge, MA, 02142, USA. 7Present address: Rubius Therapeutics, Cambridge, MA, 02139, USA. 8Present address: RPS North America, South Kingstown, RI, 02879, USA. *Correspondence: [email protected] (E.L.H.), [email protected] (J.W.H.), [email protected] (S.P.G.) #Lead Contact: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2020.01.19.905109; this version posted January 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Extending the Phenotypic Spectrum of Sengers Syndrome: Congenital Lactic Acidosis with Synthetic Liver Dysfunction
    Himmelfarb Health Sciences Library, The George Washington University Health Sciences Research Commons Pathology Faculty Publications Pathology 4-13-2018 Extending the phenotypic spectrum of Sengers syndrome: Congenital lactic acidosis with synthetic liver dysfunction. David B Beck Kristina Cusmano-Ozog George Washington University Nickie Andescavage George Washington University Eyby Leon George Washington University Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/smhs_path_facpubs Part of the Medical Pathology Commons, Pathology Commons, and the Translational Medical Research Commons APA Citation Beck, D., Cusmano-Ozog, K., Andescavage, N., & Leon, E. (2018). Extending the phenotypic spectrum of Sengers syndrome: Congenital lactic acidosis with synthetic liver dysfunction.. Translational Science of Rare Diseases, 3 (1). http://dx.doi.org/10.3233/ TRD-180020 This Journal Article is brought to you for free and open access by the Pathology at Health Sciences Research Commons. It has been accepted for inclusion in Pathology Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please contact [email protected]. Translational Science of Rare Diseases 3 (2018) 45–48 45 DOI 10.3233/TRD-180020 IOS Press Original Research Extending the phenotypic spectrum of Sengers syndrome: Congenital lactic acidosis with synthetic liver dysfunction David B. Becka, Kristina Cusmano-Ozogb, Nickie Andescavagec and Eyby Leonb,∗ aNational Human Genome Research Institute, National Institute of Health, Bethesda, MD, USA bChildren’s National Health System, Rare Disease Institute, Genetics and Metabolism, Washington, DC, USA cChildren’s National Health System, Pediatrics, Neonatology, Washington, DC, USA Abstract. Sengers syndrome is a rare autosomal recessive mitochondrial disease characterized by lactic acidosis, hypertrophic cardiomyopathy and bilateral cataracts.
    [Show full text]
  • Mapping of Leptin and Its Syntenic Genes to Chicken Chromosome
    Edinburgh Research Explorer Mapping of leptin and its syntenic genes to chicken chromosome 1p Citation for published version: Seroussi, E, Pitel, F, Leroux, S, Morisson, M, Bornelöv, S, Miyara, S, Yosefi, S, Cogburn, LA, Burt, DW, Anderson, L & Friedman-Einat, M 2017, 'Mapping of leptin and its syntenic genes to chicken chromosome 1p', BMC Genetics, vol. 18, no. 1, pp. 77. https://doi.org/10.1186/s12863-017-0543-1 Digital Object Identifier (DOI): 10.1186/s12863-017-0543-1 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: BMC Genetics General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 07. Oct. 2021 Seroussi et al. BMC Genetics (2017) 18:77 DOI 10.1186/s12863-017-0543-1 RESEARCHARTICLE Open Access Mapping of leptin and its syntenic genes to chicken chromosome 1p Eyal Seroussi1*, Frédérique Pitel2, Sophie Leroux2, Mireille Morisson2, Susanne Bornelöv3, Shoval Miyara1, Sara Yosefi1, Larry A. Cogburn4, David W. Burt5, Leif Anderson3,6,7 and Miriam Friedman-Einat1* Abstract Background: Misidentification of the chicken leptin gene has hampered research of leptin signaling in this species for almost two decades.
    [Show full text]
  • Mitochondrial Rab Gaps Govern Autophagosome Biogenesis During Mitophagy Koji Yamano1, Adam I Fogel1, Chunxin Wang1, Alexander M Van Der Bliek2, Richard J Youle1*
    RESEARCH ARTICLE elife.elifesciences.org Mitochondrial Rab GAPs govern autophagosome biogenesis during mitophagy Koji Yamano1, Adam I Fogel1, Chunxin Wang1, Alexander M van der Bliek2, Richard J Youle1* 1Biochemistry Section, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, United States; 2Department of Biological Chemistry, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, United States Abstract Damaged mitochondria can be selectively eliminated by mitophagy. Although two gene products mutated in Parkinson’s disease, PINK1, and Parkin have been found to play a central role in triggering mitophagy in mammals, how the pre-autophagosomal isolation membrane selectively and accurately engulfs damaged mitochondria remains unclear. In this study, we demonstrate that TBC1D15, a mitochondrial Rab GTPase-activating protein (Rab-GAP), governs autophagosome biogenesis and morphology downstream of Parkin activation. To constrain autophagosome morphogenesis to that of the cargo, TBC1D15 inhibits Rab7 activity and associates with both the mitochondria through binding Fis1 and the isolation membrane through the interactions with LC3/ GABARAP family members. Another TBC family member TBC1D17, also participates in mitophagy and forms homodimers and heterodimers with TBC1D15. These results demonstrate that TBC1D15 and TBC1D17 mediate proper autophagic encapsulation of mitochondria by regulating Rab7 activity at the interface between mitochondria and isolation membranes. DOI: 10.7554/eLife.01612.001 *For correspondence: [email protected] Introduction Competing interests: See page 21 Autophagosomes enclose seemingly random portions of the cytoplasm to supply nutrients during starvation or they can specifically engulf cellular debris to maintain quality control (Mizushima et al., Funding: See page 21 2011).
    [Show full text]
  • Two Novel Mutations in the AGK Gene: Two Case Reports with Sengers
    Techno e lo Kor et al., Gene Technol 2016, 5:1 n g e y G Gene Technology DOI: 10.4172/2329-6682.1000140 ISSN: 2329-6682 Case Report Open Access Two Novel Mutations in the AGK Gene: Two Case Reports with Sengers Syndrome Deniz Kor1*, Berna Seker Yılmaz1, Ozden Ozgur Horoz2, Gulay Ceylaner3, Selcuk Sızmaz4, Fadli Demir2 and Neslihan Onenli Mungan1 1Department of Pediatric Metabolism and Nutrition, Faculty of Medicine, Cukurova University, Adana, Turkey 2Department of Pediatrics, Faculty of Medicine, Cukurova University, Adana, Turkey 3Intergen Genetic Laboratory, Ankara, Turkey 4Department of Ophthalmology, Cukurova University Faculty of Medicine, Adana, Turkey Abstract Mutations in the AGK gene are known to cause Sengers Syndrome, a rare recessive disorder characterized by congenital cataracts, hypertrophic cardiomyopathy, skeletal myopathy, exercise intolerance and lactic acidosis with normal mental development. Since the first report in 1975 by Sengers et al. about 50 individuals have been described as having this syndrome. Here we report two novel mutations in the AGK gene in two patients with neonatal Sengers syndrome. Keywords: AGK gene; Sengers syndrome; Cardiomyopathy; acylcarnitine levels, plasma amino acids and urine organic acids) Myopathy; Cataract were within normal limits except elevated levels of creatine kinases and lactate. Echocardiographic evaluation documented hypertrophic Introduction cardiomyopathy with an ejection fraction of 30%. Electromyography Sengers Syndrome (OMIM 212350), also known as cardiomyopathic and cerebral MRI showed no abnormality. A quadriceps muscle biopsy mitochondrial DNA depletion syndrome-10 (MTDPS10) is a rare revealed fatty infiltrations in the muscle fibers and myopathic changes. autosomal-recessive disorder characterized by congenital cataracts, Based on these observations a clinical diagnosis of Sengers Syndrome hypertrophic cardiomyopathy, skeletal myopathy, exercise intolerance was made.
    [Show full text]
  • Distinct Genetic Alterations in Colorectal Cancer
    Distinct Genetic Alterations in Colorectal Cancer Hassan Ashktorab1*, Alejandro A. Scha¨ffer2, Mohammad Daremipouran3, Duane T. Smoot3, Edward Lee3, Hassan Brim3 1 Department of Medicine and Cancer Center, Howard University, College of Medicine, Washington, DC, United States of America, 2 National Center for Biotechnology Information, National Institutes of Health (NIH), Department of Health and Human Services (DHHS), Bethesda, Maryland, United States of America, 3 Department of Pathology, Howard University, College of Medicine, Washington, DC, United States of America Abstract Background: Colon cancer (CRC) development often includes chromosomal instability (CIN) leading to amplifications and deletions of large DNA segments. Epidemiological, clinical, and cytogenetic studies showed that there are considerable differences between CRC tumors from African Americans (AAs) and Caucasian patients. In this study, we determined genomic copy number aberrations in sporadic CRC tumors from AAs, in order to investigate possible explanations for the observed disparities. Methodology/Principal Findings: We applied genome-wide array comparative genome hybridization (aCGH) using a 105k chip to identify copy number aberrations in samples from 15 AAs. In addition, we did a population comparative analysis with aCGH data in Caucasians as well as with a widely publicized list of colon cancer genes (CAN genes). There was an average of 20 aberrations per patient with more amplifications than deletions. Analysis of DNA copy number of frequently altered chromosomes revealed that deletions occurred primarily in chromosomes 4, 8 and 18. Chromosomal duplications occurred in more than 50% of cases on chromosomes 7, 8, 13, 20 and X. The CIN profile showed some differences when compared to Caucasian alterations. Conclusions/Significance: Chromosome X amplification in male patients and chromosomes 4, 8 and 18 deletions were prominent aberrations in AAs.
    [Show full text]
  • Comprehensive Array CGH of Normal Karyotype Myelodysplastic
    Leukemia (2011) 25, 387–399 & 2011 Macmillan Publishers Limited All rights reserved 0887-6924/11 www.nature.com/leu LEADING ARTICLE Comprehensive array CGH of normal karyotype myelodysplastic syndromes reveals hidden recurrent and individual genomic copy number alterations with prognostic relevance A Thiel1, M Beier1, D Ingenhag1, K Servan1, M Hein1, V Moeller1, B Betz1, B Hildebrandt1, C Evers1,3, U Germing2 and B Royer-Pokora1 1Institute of Human Genetics and Anthropology, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany and 2Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Duesseldorf, Germany About 40% of patients with myelodysplastic syndromes (MDSs) 40–50% of MDS cases have a normal karyotype. MDS patients present with a normal karyotype, and they are facing different with a normal karyotype and low-risk clinical parameters are courses of disease. To advance the biological understanding often assigned into the IPSS low and intermediate-1 risk groups. and to find molecular prognostic markers, we performed a high- resolution oligonucleotide array study of 107 MDS patients In the absence of genetic or biological markers, prognostic (French American British) with a normal karyotype and clinical stratification of these patients is difficult. To better prognosticate follow-up through the Duesseldorf MDS registry. Recurrent these patients, new parameters to identify patients at higher risk hidden deletions overlapping with known cytogenetic aberra- are urgently needed. With the more recently introduced modern tions or sites of known tumor-associated genes were identi- technologies of whole-genome-wide surveys of genetic aberra- fied in 4q24 (TET2, 2x), 5q31.2 (2x), 7q22.1 (3x) and 21q22.12 tions, it is hoped that more insights into the biology of disease (RUNX1, 2x).
    [Show full text]